



HEALTH PARTNERS PLANS
PRIOR AUTHORIZATION REQUEST FORM

Health Partners Plans

Zeposia

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Form with fields: Patient Name, Prescriber Name, HPP Member Number, Date of Birth, Patient Primary Phone, Address, City, State ZIP, Line of Business, Drug Name, Quantity, Directions, Diagnosis Code, Diagnosis.

HPP's maximum approval time is 12 months but may be less depending on the drug.

Please attach any pertinent medical history including labs and information for this member that may support approval.

Please answer the following questions and sign.

Q1. Is this request for continuation of therapy with Zeposia (ozanimod)?

Yes No

Q2. Is prescribed Zeposia (ozanimod) for the treatment of a diagnosis that is indicated in the U.S. Food and Drug Administration (FDA)-approved package labeling or a medically accepted indication?

Yes No

Q3. Is prescribed Zeposia (ozanimod) by or in consultation with an appropriate specialist (i.e., a neurologist for a diagnosis of multiple sclerosis or a gastroenterologist for a diagnosis of ulcerative colitis)?

Yes No

Q4. Does the patient have a contraindication to Zeposia (ozanimod)?

Yes No

Q5. Does the patient have a diagnosis of multiple sclerosis?

Yes No

Q6. Does the patient have a history of therapeutic failure of or a contraindication or an intolerance to the preferred Multiple Sclerosis Agents approved for the beneficiary's diagnosis (such as Aubagio, Avonex, Betaseron, Dalfampridine ER Tablet, Dimethyl Fumarate, Gilenya, Glatiramer, Glatopa, Rebif, Rebif Rebidose, Tysabri)?

Yes No

Q7. Does the patient have a current history (within the past 90 days) of being prescribed Zeposia (ozanimod)?



HEALTH PARTNERS PLANS
PRIOR AUTHORIZATION REQUEST FORM

Health Partners Plans

Zeposia

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name: Prescriber Name:

Q8. Does the patient have a diagnosis of ulcerative colitis (UC)?
Q9. Does the patient have a diagnosis of mild UC that is associated with multiple poor prognostic factors OR moderate to severe UC?
Q10. Has the patient 1) Failed to achieve remission with or has a contraindication or an intolerance to an induction course of corticosteroids; 2) Failed to maintain remission with an immunomodulator in accordance with current consensus guidelines... OR 3) Has achieved remission with Zeposia (ozanimod) AND will be using Zeposia (ozanimod) as maintenance therapy to maintain remission?
Q11. Does the patient have a history of therapeutic failure of or a contraindication or an intolerance to the preferred Cytokine and CAM Antagonists approved or medically accepted for treatment of UC or has a current history (within the past 90 days) of being prescribed Zeposia (ozanimod)?
Q12. Is prescribed a dose that is consistent with the FDA-approved package labeling, nationally recognized compendia, or peer-reviewed medical literature and is age-appropriate according to FDA-approved package labeling, nationally recognized compendia, or peer-reviewed literature?
Q13. Is the patient prescribed Zeposia (ozanimod) by or in consultation with an appropriate specialist (i.e., a neurologist for a diagnosis of multiple sclerosis or a gastroenterologist for a diagnosis of ulcerative colitis)?
Q14. Is the patient prescribed a dose that is consistent with FDA-approved package labeling, nationally recognized compendia, or peer-reviewed medical literature?
Q15. Does the patient have a contraindication to Zeposia (ozanimod)?
Q16. Does the patient have a diagnosis of multiple sclerosis?

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document



HEALTH PARTNERS PLANS
PRIOR AUTHORIZATION REQUEST FORM

Health Partners Plans

Zeposia

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name:	Prescriber Name:
---------------	------------------

<p>Q17. Does the patient have documented improvement or stabilization of the multiple sclerosis disease course?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q18. Does the patient have a diagnosis of UC?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q19. Has the patient experienced improvement in disease activity and/or level of functioning since starting Zeposia (ozanimod)?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q20. Additional Information:</p>

Prescriber Signature

Date

Updated for 2022